English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We read with interest the important article by Rao et al.1 Using publicly available data from the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator (NINDS-tPA) trials, the authors compared 4 definitions of intracranial hemorrhage (ICH) after thrombolysis to identify the most clinically relevant. They conclude that the European Cooperative Acute Stroke Study 2 (ECASS-2) and Modified Safe Implementation of Thrombolysis in Stroke-Monitoring Study (mSITS-MOST) definitions best identify tissue-type plasminogen activator hemorrhages that alter final outcome, but that their results favor the ECASS-2 definition, in line with previous reports.One important feature of the ECASS-2 definition is that it encompasses minor ICH, sometimes unlikely to cause neurological deterioration such as hemorrhagic infarction type 1 or 2. In relation to this, we are puzzled by the fate of the 6 patients (No. 22–27) who had a symptomatic ICH according to ECASS-2 and were all dead at 3 months, yet did not have parenchymal hemorrhage, raising the question whether these patients’ …

stroke

Letter by Turc et al Regarding Article, “Defining Clinically Relevant Cerebral Hemorrhage After Thrombolytic Therapy for Stroke: Analysis of the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Trials”